Suberoylanilide hydroxamic acid (SAHA), which is FDA approved for the treatment of cancer under the trade name Zolinza?, was effective in restoring memory performance in this Alzheimer's disease (AD) model. 

SAHA was synthesized by Medicilon and was given to mice as 50?mg/kg doses. Injections (10?mL/kg) were given intraperitoneally and were alternated daily between left and right sides of the abdomen. Chronic treatments of SAHA completely restored performance deficits in APP/PS1 mice.

Reference

Mark Kilgore, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2010 Mar;35(4):870-80. doi: 10.1038/npp.2009.197.